ArticleCancer research2018
Helicase-Driven Activation of NFκB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment.
Open access · greenAbstract read
In one paragraph
Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Relevance of humanized three-dimensional tumor tissue models: a descriptive systematic literature review.Cellular and molecular life sciences : CMLS · 2020Pooled it
- Trial
- TRIM56 Promotes Antiviral Responses Downstream of TLR4.Viruses · 2026Article
- Synergy between TLR3-ligand and IFN-α in the transient sensitization of "Cold" tumors to PD-1 blockade and the induction of systemic immunity.Journal for immunotherapy of cancer · 2025Article
- Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy.Journal for immunotherapy of cancer · 2025Review
- Meeting Highlights The 4th Marie Skłodowska-Curie Symposium on cancer research and care: Mechanisms of support for regional & international collaborations.Wiadomosci lekarskie (Warsaw, Poland : 1960) · 2025Article
- Immunosuppressive mechanisms and therapeutic targeting of regulatory T cells in ovarian cancer.Frontiers in immunology · 2025Review
- IFNγ-mediated suppression of alternative NF-κB in tumor-resident myeloid cells promotes selective recruitment of cytotoxic but not regulatory T cells.Frontiers in immunology · 2025Article
- cGAS/STING signaling pathway in gynecological malignancies: From molecular mechanisms to therapeutic values.Frontiers in immunology · 2025Review
- Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer.Journal for immunotherapy of cancer · 2024Article
- Dendritic Cell Plasticity, Radiation, and Newton's Third Law.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Review
- Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx.Journal for immunotherapy of cancer · 2023Article
- Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).Journal of translational medicine · 2023Article
- Two Modes of Th1 Polarization Induced by Dendritic-Cell-Priming Adjuvant in Vaccination.Cells · 2023Review
- Review
- Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors.NPJ breast cancer · 2022Review
- Cancer vaccines: the next immunotherapy frontier.Nature cancer · 2022Review
- Metabolic Adaptation-Mediated Cancer Survival and Progression in Oxidative Stress.Antioxidants (Basel, Switzerland) · 2022Review
- Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Marie-Nicole TheodorakiDepartment of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Saigopalakrishna YerneniDepartment of Biomedical Engineering, College of Engineering, Carnegie Mellon University, Pittsburgh, PA.
Saumendra N SarkarDepartment of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0002-2850-6121
Brian OrrMagee-Women's Research Institute, Ovarian Cancer Center of Excellence, Peritoneal/Ovarian Cancer Specialty Care Center, UPMC Hillman Cancer Center, and Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania.
Ravikumar MuthuswamyDepartment of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Jamie VoytenDepartment of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Francesmary ModugnoUniversity of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.
Weijian JiangDepartment of Medicine and Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York.
Melissa GrimmDepartment of Medicine and Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York.
Per H BasseDepartment of Medicine and Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York.
David L BartlettDepartment of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Robert P EdwardsUniversity of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.
Pawel KalinskiDepartment of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania. Pawel.Kalinski@RoswellPark.org.
University of Pittsburgh · USRoswell Park Comprehensive Cancer Center · USMagee-Womens Research Institute · USCarnegie Mellon University · USUPMC Hillman Cancer Center · US
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0MRPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B. · 2013 to 2025
$19.6MTargeting the Chemokine System to Sensitize Tumors to ImmunotherapyP01CA234212 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI KALINSKI, PAWEL · 2020 to 2024
$10.1MType-1 Antigen Presenting Cells in CNS Tumors - Key to Efficient Anti-Tumor T-CelP01CA132714 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KALINSKI, PAWEL · 2009 to 2013
$6.8MDifferential modulation of RIG-I and cGAS signaling by OASL and its role in antiviral response.R01AI118896 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SARKAR, SAUMENDRA N · 2015 to 2019
$2.1MNCI NIH HHS P01 CA132714NCI NIH HHS P01 CA234212NCI NIH HHS P30 CA047904NCI NIH HHS P50 CA159981NIAID NIH HHS R01 AI118896
Abstract
Presence of cytotoxic CD8
Indexed as
AdultAgedAnimalsCD8-Positive T-LymphocytesCyclooxygenase 2FemaleHumansImmune ToleranceInflammationInterferon Regulatory Factor-3MiceMice, Inbred C57BLMiddle AgedNF-kappa BOvarian NeoplasmsRatsCyclooxygenase 2Interferon Regulatory Factor-3NF-kappa BRNA, Double-StrandedRNA HelicasesTumor Necrosis Factor-alpha
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.